Halozyme Therapeutics Inc (HALO) may enjoy gains as insiders got busy in the recent days

Halozyme Therapeutics Inc’s filing revealed that its PRESIDENT AND CEO Torley Helen unloaded Company’s shares for reported $1.29 million on Aug 13 ’25. In the deal valued at $64.32 per share,20,000 shares were sold. As a result of this transaction, Torley Helen now holds 733,719 shares worth roughly $50.6 million.

Then, Torley Helen sold 20,000 shares, generating $1,270,121 in total proceeds. Upon selling the shares at $63.51, the PRESIDENT AND CEO now owns 733,719 shares.

Before that, Torley Helen sold 20,000 shares. Halozyme Therapeutics Inc shares valued at $1,260,917 were divested by the PRESIDENT AND CEO at a price of $63.05 per share. As a result of the transaction, Torley Helen now holds 733,719 shares, worth roughly $50.6 million.

Morgan Stanley upgraded its Halozyme Therapeutics Inc [HALO] rating to an Overweight from a an Equal-weight in a research note published recently. Morgan Stanley also remained covering HALO and has decreased its forecast on May 14, 2025 with a “an Equal-weight” recommendation from previously “an Overweight” rating. Leerink Partners revised its rating on May 13, 2025. It rated HALO as “an Underperform” which previously was an “a Market perform”.

Price Performance Review of HALO

On Monday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock jump 2.51% to $68.96. Over the last five days, the stock has gained 9.65%. Halozyme Therapeutics Inc shares have risen nearly 20.12% since the year began. Nevertheless, the stocks have risen 44.24% over the past one year. While a 52-week high of $70.50 was reached on 05/07/25, a 52-week low of $42.01 was recorded on 05/14/25.

Levels Of Support And Resistance For HALO Stock

The 24-hour chart illustrates a support level at 68.26, which if violated will result in even more drops to 67.55. On the upside, there is a resistance level at 69.36. A further resistance level may holdings at 69.75.

How much short interest is there in Halozyme Therapeutics Inc?

A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2025-07-31, dropping by -0.24 million shares to a total of 9.93 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 10.18 million shares. There was a decline of -2.45%, which implies that there is a negative sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.